The American Society for Microbiology (ASM) Microbe 2019 meeting runs from 20 to 24 June. Motif bosses will be presenting their posters on 21 and 22 June.
AIM- and Nasdaq-listed Motif met with the US Food and Drug Administration (FDA) earlier this month as it looks to secure regulatory approval for iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).
The company sought talks after the FDA declined to give the antibiotic the green light, citing in a document the need for additional data on liver toxicity.
As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’. The firm has always said it was keen to discuss potential deficiencies with the information provided.
The latest meeting, which took place on 3 May, offered that chance, with feedback expected within 30 days.